• Je něco špatně v tomto záznamu ?

Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan

V. Zídek, P. Mlejnek, M. Simáková, J. Silhavy, V. Landa, L. Kazdová, M. Pravenec, TW. Kurtz,

. 2013 ; 26 (6) : 829-35.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14040923
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do 2015-12-31
Health & Medicine (ProQuest) od 2000-01-01 do 2015-12-31

BACKGROUND: The angiotensin receptor blocker telmisartan has unique chemical properties that enable it to partially activate the peroxisome proliferator activated receptor gamma (PPARG) as well as block angiotensin II type 1 receptors. METHODS: To directly test whether some of the metabolic effects of telmisartan require the presence of PPARG, we studied mice in which the gene (Pparg) for PPARG had been deleted in fat or in muscle. RESULTS: We found that knockout of Pparg in fat tissue greatly impaired the ability of telmisartan to increase adiponectin levels and to enhance sensitivity to insulin-stimulated glucose incorporation into adipose tissue lipids. In contrast, muscle-specific Pparg knockout had relatively little or no impact on the ability of telmisartan to increase adiponectin levels or affect glucose metabolism either in fat or muscle. These findings provide compelling evidence that the ability of telmisartan to increase adiponectin levels and stimulate glucose use in adipose tissue may depend on the presence of PPARG in fat. CONCLUSIONS: We conclude that PPARG in adipose tissue is required for at least several of the metabolic actions of telmisartan.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14040923
003      
CZ-PrNML
005      
20140110114413.0
007      
ta
008      
140107s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ajh/hpt019 $2 doi
035    __
$a (PubMed)23426788
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zídek, Václav
245    10
$a Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan / $c V. Zídek, P. Mlejnek, M. Simáková, J. Silhavy, V. Landa, L. Kazdová, M. Pravenec, TW. Kurtz,
520    9_
$a BACKGROUND: The angiotensin receptor blocker telmisartan has unique chemical properties that enable it to partially activate the peroxisome proliferator activated receptor gamma (PPARG) as well as block angiotensin II type 1 receptors. METHODS: To directly test whether some of the metabolic effects of telmisartan require the presence of PPARG, we studied mice in which the gene (Pparg) for PPARG had been deleted in fat or in muscle. RESULTS: We found that knockout of Pparg in fat tissue greatly impaired the ability of telmisartan to increase adiponectin levels and to enhance sensitivity to insulin-stimulated glucose incorporation into adipose tissue lipids. In contrast, muscle-specific Pparg knockout had relatively little or no impact on the ability of telmisartan to increase adiponectin levels or affect glucose metabolism either in fat or muscle. These findings provide compelling evidence that the ability of telmisartan to increase adiponectin levels and stimulate glucose use in adipose tissue may depend on the presence of PPARG in fat. CONCLUSIONS: We conclude that PPARG in adipose tissue is required for at least several of the metabolic actions of telmisartan.
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x farmakokinetika $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a benzimidazoly $x farmakokinetika $7 D001562
650    _2
$a benzoáty $x farmakokinetika $7 D001565
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a hypertenze $x farmakoterapie $x metabolismus $7 D006973
650    _2
$a inzulinová rezistence $7 D007333
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a PPAR gama $x biosyntéza $7 D047495
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mlejnek, Petr $u -
700    1_
$a Simáková, Miroslava $u -
700    1_
$a Silhavy, Jan $u -
700    1_
$a Landa, Vladimír $u -
700    1_
$a Kazdová, Ludmila $u -
700    1_
$a Pravenec, Michal $u -
700    1_
$a Kurtz, Theodore W $u -
773    0_
$w MED00000255 $t American journal of hypertension $x 1941-7225 $g Roč. 26, č. 6 (2013), s. 829-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23426788 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140107 $b ABA008
991    __
$a 20140110115115 $b ABA008
999    __
$a ok $b bmc $g 1005319 $s 839435
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 26 $c 6 $d 829-35 $i 1941-7225 $m American journal of hypertension $n Am J Hypertens $x MED00000255
LZP    __
$a Pubmed-20140107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...